License Grant Fee. 9.2.1 Upon exercise of the Option and *** after the date of receipt of the corresponding invoice, Servier shall pay MacroGenics a non-refundable, non-creditable payment (the “License Grant Fee”) of
(a) if by the date of the exercise of the Option, ***; or
(b) if by the date of the exercise of the Option, ***; or
(c) if by the date of the exercise of the Option, ***.
9.2.2 If Servier pays MacroGenics the License Grant Fee according to Section 9.2.1(a) or (b), Servier will, within *** after the date of receipt of the corresponding invoice, pay MacroGenics *** until Servier has paid MacroGenics a total of thirty million ($30,000,000) under Sections 9.2.1 and 9.2.2.
License Grant Fee. Coherus shall pay to Genentech a one-time, non-creditable, non-refundable license grant fee of [***].
License Grant Fee. Within thirty (30) calendar days after the Effective Date, Lorus shall pay to Genentech a one time non-creditable, non-refundable license grant fee REDACTED – LICENSE FEE.
License Grant Fee. (a) Within sixty (60) days after execution of this Agreement, Licensee shall pay to Genentech a non-creditable, non-refundable initial installment license grant fee of $[*] and
(b) Within thirty (30) days of filing an NDA or BLA or equivalent for any indication, Licensee shall pay to Genentech a non-creditable, non-refundable final installment license grant fee of $[*].
License Grant Fee. 3.1 In consideration for the license granted under paragraph 2.1, Licensee agrees to pay to Licensor a [*****] license grant fee of [*****] United States dollars payable within [*****] following the execution of this Agreement.
3.2 Licensee further agrees to pay Licensor an annual license maintenance fee in the sum of [*****] payable beginning [*****] from the end of the [*****] following the EFFECTIVE DATE of this Agreement and continuing [*****] for the life of this Agreement.
3.3 In consideration of the license granted in paragraph 2.2, Licensee shall [*****] grant to Licensor a first option for a license to make, use, import, offer and sell in the research reagent market, as described below, at least [*****], but no more than [*****] of Licensee's [*****]. Such enzymes shall be selected from (i) Licensee's [*****] DNA modifying [*****] enzymes [*****] or (ii) novel DNA modifying [*****] enzymes [*****] during the term of the Agreement provided; however, that [*****] ((i) and (ii) are collectively referred to below as [*****]). Prior to transfer, Licensee will provide [*****] as well as other information if available, for the [*****] and [*****]. In the event that Licensor finds that any such [*****] as represented by
License Grant Fee. Within thirty (30) days after amendment of Schedule A to add an Antigen thereto, Licensee shall pay to Genentech a non-creditable, non-refundable license grant fee of $[***] per Antigen.
License Grant Fee. Licensee shall pay to Genentech a non-creditable, nonrefundable license grant fee of [***] in two (2) separate payments, a first payment of [***] within ten (10) business days after the Effective Date, a second payment of [***] on the day that the first human patient is dosed with Licensed Product in a clinical trial.
License Grant Fee. Within ten (10) calendar days following the Effective Date, which shall be April 3rd 2004, Licensee shall pay DTC Two million U.S. Dollars ($2,000,000 US).
License Grant Fee. As partial consideration for the license and other rights granted under this Agreement, Licensee, within [***] after the Effective Date, shall pay to Licensor a non-refundable, non-creditable license grant fee of Three Hundred Thousand US Dollars ($300,000). Notwithstanding anything to the contrary in Section 12.2(a), if Licensee fails to deliver said fee to Licensor within [***] following the Effective Date, Licensor may [***].
License Grant Fee. Within fifteen (15) days after the Effective Date, AVIGEN shall pay to BTG a non-refundable, non-creditable license grant fee of [ * ].
